At present, updated secondary implant stability data generated by actual versions of resonance frequency analysis (RFA) and mobility measurement (MM) electronic devices of 2 different implant systems with actual manufactured surfaces seem to lack and/or are incomplete. Secondary implant stability data based on both RFA and MM measurements were collected and analyzed from 44 formerly treated patients (24 f, 20 m) that received either Ankylos Cellplus (Ø3.5mm) (A) (n=36) or Straumann regular neck SLA tissue level (Ø4.1mm) (S) (n=37) implants in posterior positions of both jawbones (total number= 72). These results were interpretated in view of formerly published data. Estimated RFA outcomes (mean±SD) for A implants were of 81.23 (±0.65) (LP) - 76.15 (±1.57) (UP) isq; for S implants 76.15 (±1.48) (LP) - 73.88 (±2.34) (UP) isq. Estimated MM outcomes for A implants were (-4.0) (±0.23) (LP) - (-3.2) (±0.33) (UP) ptv; for S implants (-5.15) (±0.39) (LP) - (-4.4) (±0.84) (UP) ptv. According to GEE statistical modelling, implant type and ? position seems to influence the outcome variables (p<0.05), gender and implant length did not (p >0.05). Secondary implant stability values, recorded with current RFA and MM devices, of A Cellplus implants are provided for the first time. A difference of 14.7-9.7 isq values was noted for CellPlus versus TPS S implants recorded with a cabled RFA device. This study supports the assumption that RFA outcomes generated with first generation RFA devices are different from those obtained with current RFA devices, meaning that its use in reviews need caution and correction.